OrbiMed Portfolio holdings
OrbiMed is an investment manager focused exclusively on healthcare, running public equity, private equity and private credit and royalty funds. The firm traces its origins to 1989, when Viren Mehta and Samuel Isaly, both pharmaceutical analysts at the bank S.G Warburg, set up the research and money-management firm Mehta & Isaly; in 1998 it split in two, with Isaly forming OrbiMed and Mehta forming Mehta Partners. Its public equity side covers long/short funds built around corporate events as well as closed-end investment trusts, and OrbiMed launched its first dedicated venture capital fund in 2000 and its first royalty and credit fund in 2011. Carl Gordon, Carter Neild and Geoffrey Hsu form the committee that leads the firm, which is owned and controlled by eight members.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$59.7M |
| 2 |
Odyssey Therapeutics
ODTX
|
+$52.6M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
+$47.6M |
| 4 |
Cogent Biosciences
COGT
|
+$47.6M |
| 5 |
Humana
HUM
|
+$46.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$54.7M |
| 2 |
Danaher
DHR
|
+$50.4M |
| 3 |
Enliven Therapeutics
ELVN
|
+$50.2M |
| 4 |
Boston Scientific
BSX
|
+$48.8M |
| 5 |
Disc Medicine
IRON
|
+$48.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.03% |
| 2 | Miscellaneous | 2.97% |
Similar funds
OrbiMed's Q2 2026 Portfolio in Review
As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.
- OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
- OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
- OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
- OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
- OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
- OrbiMed opened 38 new positions and closed 23 in Q2 2026.
- OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.
Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.